Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
In a letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed concerns regarding two provisions in the 2021 Affordable Care Act (ACA) Notice of Benefit and Payment Parameters proposed rule. This proposal, if implemented, would update the regulatory and financial standards applied to ACA Exchanges.
In a letter to Representatives Terri Sewell (D-AL), Adrian Smith (R-NE), Tony Cárdenas (D-CA), and John Shimkus (R-IL), the Association for Clinical Oncology (ASCO) conveyed its support for legislation the lawmakers introduced in the U.S. House of Representatives. The bill, H.R.
Statement By American Society of Clinical Oncology (ASCO) President Howard A. “Skip” Burris III, MD, FACP, FASCO “We commend the U.S. Food and Drug Administration (FDA) for releasing draft guidance to encourage inclusion of older adults in clinical trials of drugs for the treatment of cancer. We thank Richard Pazdur, MD, director of the FDA Oncology Center of Excellence, for his leadership on this important issue.
The American Society of Clinical Oncology (ASCO) released a position statement on drug repository programs that outlined ASCO’s support for such programs--for oral medications that are maintained within a closed system--and recommended ways to help ensure appropriate implementation. 
On February 18, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring. Read more. 
ASCO recently released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” urging state and federal policymakers not to enact, apply for, or advance any proposals to establish block grants for Medicaid programs. Read more.
The American Society of Clinical Oncology (ASCO) today released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ensure that these programs are implemented appropriately, with sufficient patient protections in place. Read more. 
The American Society of Clinical Oncology’s latest policy brief provides an overview of the issues complicating health care price transparency, the society’s concerns about how the lack of price transparency in the health care system is impacting people with cancer, and how drug manufacturers, pharmacy benefit managers, and other stakeholders can be more transparent in a way that is meaningful for patients and providers. Read the bri